The Association between Polymorphism of the Dopamine D3 Receptors and Concentrations of Plasma Homovanillic and 5-hydroxyindoleacetic Acid, and Therapeutic Response of chronic Schizophrenic Patients.
- Author:
Geo Jang JEONG
;
Min Soo LEE
;
Sang Yoon KIM
;
Dae Yeop KANG
;
Dong Il KWAK
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Dopamine D3 receptor gene;
Ser-9-Gly polymorphism;
Homovanillic acid;
5-Hydroxyindoleacetic acid
- MeSH:
Alleles;
Antipsychotic Agents;
Chromatography, High Pressure Liquid;
Dopamine*;
Genotype;
Homovanillic Acid;
Humans;
Hydroxyindoleacetic Acid;
Plasma*;
Prognosis;
Receptors, Dopamine D3*;
Receptors, Serotonin;
Schizophrenia;
Weights and Measures
- From:Journal of the Korean Society of Biological Psychiatry
2001;8(1):116-122
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Schizophrenia manifests a variety of interindividual differences in therapeutic response to antipsychotics. This might be attributable to dopamine and serotonin receptors that a important target for various antipsychotics, and the D3 receptor(DRD3) alleles they carry. The purpose of our study was to investigate whether the plasma levels of homovanillic acid(HVA) and 5-hydroxyindoleacetic acid(HIAA), and the polymorphism of DRD3 can be held as a predictor of treatment response ni chronic schizophrenic patients. METHODS: Therapeutic response for 16 korean schizophrenia patient treated during 48 weeks were assessed by PANSS used as the clinical symptom rating scales. The levels of concentration of HVA and 5-HIAA were examined by HPLC at baseline and at 48 weeks. We classified the polymorphism of DRD3 receptor using amplifying by polymerase chain reaction(PCR). RESULTS: Neither concentrations of HVA and 5-HIAA nor genotype of dopamine 3 receptor were not significantly associated with the therapeutic response. But, the patients who has A1 alleles of DRD3 gene showed poor therapeutic responses. CONCLUSION: A1 allele of DRD3 gene is associated with poor prognosis of chronic schizophrenia.
